SKF 38393-A未能缓解狨猴中由1-甲基-4-苯基-1,2,3,6-四氢吡啶诱发的帕金森氏症症状。
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
作者信息
Close S P, Marriott A S, Pay S
出版信息
Br J Pharmacol. 1985 Jun;85(2):320-2. doi: 10.1111/j.1476-5381.1985.tb08863.x.
Abstract
Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets. These symptoms were reduced by L-DOPA plus benserazide but the putative D1-receptor agonist SKF 38393-A did not affect tremor and increased the bradykinesia. Neither treatment affected behaviour in normal marmosets. It is suggested that D1-receptor agonists are unlikely to be effective in the treatment of Parkinson's disease.
摘要
长期给予1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）会使狨猴出现帕金森氏症症状，主要为运动迟缓及震颤。左旋多巴加苄丝肼可减轻这些症状，但假定的D1受体激动剂SKF 38393-A对震颤没有影响，反而加重了运动迟缓。两种治疗方法均未影响正常狨猴的行为。这表明D1受体激动剂不太可能有效治疗帕金森病。
相似文献
1
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.SKF 38393-A未能缓解狨猴中由1-甲基-4-苯基-1,2,3,6-四氢吡啶诱发的帕金森氏症症状。
Br J Pharmacol. 1985 Jun;85(2):320-2. doi: 10.1111/j.1476-5381.1985.tb08863.x.
2
The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.多巴胺D2激动剂LY 141865可逆转普通狨猴中由1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）诱导的帕金森症，而D1激动剂SKF 38393则不能。
Neurosci Lett. 1985 Jun 4;57(1):37-41. doi: 10.1016/0304-3940(85)90037-0.
3
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.在MPTP处理的普通狨猴中，不同效能的苯并氮杂䓬D1多巴胺激动剂的抗帕金森病差异效应。
Psychopharmacology (Berl). 1995 Feb;117(3):275-86. doi: 10.1007/BF02246102.
4
5
The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.在帕金森病的灵长类和啮齿类动物模型中，将不同效能的苯并氮杂卓D1多巴胺激动剂与喹吡罗联合使用时的差异行为效应。
Psychopharmacology (Berl). 1995 Feb;117(3):287-97. doi: 10.1007/BF02246103.
6
The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset.
Neurosci Lett. 1988 Nov 11;93(2-3):275-80. doi: 10.1016/0304-3940(88)90095-x.
7
Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
Neurosci Lett. 1992 Aug 3;142(1):1-4. doi: 10.1016/0304-3940(92)90606-8.
8
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.1-甲基-4-苯基-1,2,3,6-四氢吡啶诱导普通狨猴发生帕金森病。
Neurosci Lett. 1984 Sep 7;50(1-3):85-90. doi: 10.1016/0304-3940(84)90467-1.
9
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Eur J Pharmacol. 1988 May 20;150(1-2):59-66. doi: 10.1016/0014-2999(88)90750-9.
10
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.1-甲基-4-苯基-1,2,3,6-四氢吡啶在动物体内作为帕金森病模型的作用。
J Neural Transm Suppl. 1986;20:11-39.
引用本文的文献
1
Characterization of Gα and Gα activation by catechol and non-catechol dopamine D1 receptor agonists.儿茶酚和非儿茶酚多巴胺D1受体激动剂对Gα及Gα激活的表征
iScience. 2025 Apr 3;28(5):112345. doi: 10.1016/j.isci.2025.112345. eCollection 2025 May 16.
2
D, not D, dopamine receptor activation dramatically improves MPTP-induced parkinsonism unresponsive to levodopa.D，而不是 D，多巴胺受体激动剂显著改善了对左旋多巴无反应的 MPTP 诱导的帕金森病。
Eur J Pharmacol. 2021 Feb 5;892:173760. doi: 10.1016/j.ejphar.2020.173760. Epub 2020 Dec 3.
3
Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated.1期帕金森病研究表明，多巴胺D1/D5激动剂PF-06649751安全且耐受性良好。
Neurol Ther. 2018 Dec;7(2):307-319. doi: 10.1007/s40120-018-0114-z. Epub 2018 Oct 25.
4
Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity.MPTP 处理的狨猴大脑中[14C]-2-脱氧葡萄糖摄取的短期和长期变化：与运动活动的关系。
J Neural Transm Gen Sect. 1995;101(1-3):65-82. doi: 10.1007/BF01271546.
5
The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.在帕金森病的灵长类和啮齿类动物模型中，将不同效能的苯并氮杂卓D1多巴胺激动剂与喹吡罗联合使用时的差异行为效应。
Psychopharmacology (Berl). 1995 Feb;117(3):287-97. doi: 10.1007/BF02246103.
6
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.在MPTP处理的普通狨猴中，不同效能的苯并氮杂䓬D1多巴胺激动剂的抗帕金森病差异效应。
Psychopharmacology (Berl). 1995 Feb;117(3):275-86. doi: 10.1007/BF02246102.
7
Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.在帕金森病啮齿动物和灵长类动物模型中，选择性多巴胺拮抗剂预处理对苯并氮杂卓类D1多巴胺激动剂抗帕金森病作用的影响——D1多巴胺拮抗剂在灵长类动物中的差异效应
Psychopharmacology (Berl). 1995 Feb;117(4):403-12. doi: 10.1007/BF02246211.
8
Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease.
Psychopharmacology (Berl). 1990;102(3):295-300. doi: 10.1007/BF02244093.
9
Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets.对经1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）处理的普通狨猴施用选择性D-1和D-2多巴胺能药物后的运动活动
Psychopharmacology (Berl). 1992;109(1-2):49-56. doi: 10.1007/BF02245479.
本文引用的文献
1
Pharmacological evidence for the subclassification of central dopamine receptors in the rat.大鼠中枢多巴胺受体亚分类的药理学证据。
Br J Pharmacol. 1982 Sep;77(1):185-93. doi: 10.1111/j.1476-5381.1982.tb09285.x.
2
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.人类因哌替啶类似物合成产物导致的慢性帕金森症。
Science. 1983 Feb 25;219(4587):979-80. doi: 10.1126/science.6823561.
3
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.帕金森病的灵长类动物模型：N-甲基-4-苯基-1,2,3,6-四氢吡啶对黑质致密部多巴胺能神经元的选择性破坏。
Proc Natl Acad Sci U S A. 1983 Jul;80(14):4546-50. doi: 10.1073/pnas.80.14.4546.
4
The central effects of a novel dopamine agonist.
Eur J Pharmacol. 1978 Aug 15;50(4):419-30. doi: 10.1016/0014-2999(78)90148-6.
Zotero 插件